The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy

PHASE3CompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

October 18, 2021

Study Completion Date

November 18, 2021

Conditions
Myasthenia Gravis
Interventions
DRUG

Azathioprine

The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.

DRUG

Leflunomide

The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 2 glucocorticoid + Leflunomide: Glucocorticoid (0.25mg/kg/d )plus Leflunomide 20mg/d for adult, 10mg/d for child. if no adverse events occurred , maintain the dose until 48 weeks.

Trial Locations (1)

510080

The First Affiliated Hospital, SUN YAT-SEN UNIVERSITY, Guangzhou

All Listed Sponsors
lead

First Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT01727193 - The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy | Biotech Hunter | Biotech Hunter